Email: laura@biooasischina.com   丨     Phone: +86-177-4907-8590
You are here: Home » News » Product News » PT-141 of the basic introduction

PT-141 of the basic introduction

Views:1     Author:Site Editor     Publish Time: 2021-08-16      Origin:Site

        PT-141 It is a medicine used to treat female sexual dysfunction

Palatin Technology Co., Ltd. of the United States announced on September 26 that its drug PT-141 for the treatment of female sexual dysfunction has shown positive results in a phase I clinical trial administered to normal premenopausal women.

The trial included 32 healthy female volunteers, and it evaluated the response of these women to PT-141 and placebo under visual stimulation. The results of the test found that the vaginal blood flow of PT-141 was safe and able to use the drug had a significantly greater improvement than that of placebo users (P<0.05).pt 141 peptide for sale - Oasis

The trial was sponsored by Palatin Technology Co., Ltd. and led by Dr. Raymond Rosen, professor of psychiatry and medicine at the University of Medicine and Dentistry of New Jersey, USA.

"The results of this phase I trial prove that PT-141 can promote the emergence of the initial stage of physiological stimulation in normal women." Dr. Raymond Rosen said: "The point of action of PT-141 lies in the brain area that regulates stimulation rather than the peripheral vasculature. It has been shown in this phase I trial to increase blood flow to the genitals."

Palatin Technology Co., Ltd. of the United States announced on September 26 that its drug PT-141 for the treatment of female sexual dysfunction has shown positive results in a phase I clinical trial administered to normal premenopausal women.

The trial included 32 healthy female volunteers, and it evaluated the response of these women to PT-141 and placebo under visual stimulation. The results of the test found that the vaginal blood flow of PT-141 was safe and able to use the drug had a significantly greater improvement than that of placebo users (P<0.05). The trial was sponsored by Palatin Technology Co., Ltd. and led by Dr. Raymond Rosen, professor of psychiatry and medicine at the University of Medicine and Dentistry of New Jersey, USA.

"The results of this phase I trial prove that PT-141 can promote the emergence of the initial stage of physiological stimulation in normal women." Dr. Raymond Rosen said: "The point of action of PT-141 lies in the brain area that regulates stimulation rather than the peripheral vasculature. It has been shown in this phase I trial to increase blood flow to the genitals."

Perry Molinoff, MD, Executive Vice President of Research and Development at Palatin Technologies Co., Ltd. commented: "The above encouraging results indicate that PT-141 may have pharmacological properties as an effective treatment for female sexual dysfunction. Therefore, we A phase II clinical study of PT-141 for the treatment of female sexual motivation disorder is planned to be carried out in early 2003."

According to estimates from the Journal of the American Medical Association, up to 43% of women have some female sexual dysfunction. In the United States alone, the number of women with sexual dysfunction is more than 30 million. As male sexual dysfunction and its treatment drugs have received widespread attention, many medical institutions and pharmaceutical companies are now looking for methods and drugs that can be used to treat female sexual dysfunction.

PT-141 is a peptide drug developed by Palatin Technology Co., Ltd. which is expected to be used to treat sexual dysfunction. Relevant research suggests that PT-141 produces therapeutic activity by stimulating melanocorticoid receptors in the central nervous system, which is completely different from existing drugs that directly act on the vasculature. Pre-clinical animal model studies have found that the administration of PT-141 can dramatically increase the sexual requirements of female animals. The latter is the fundamental reason that led Palatin Technology Co., Ltd. to conduct the above-mentioned phase I trial.

PT-141 is also being developed as a treatment for men's erectile dysfunction. Two days ago (September 24), Palatin Technology Co., Ltd. just announced the positive results of the clinical trial of PT-141 for the treatment of male sexual dysfunction IIa at the annual meeting of the International Society for the Study of Sexuality and Impotence in Montreal, Canada. Palatin Technology Co., Ltd. plans to begin this fall to evaluate the IIb study of home-administered PT-141 for the treatment of erectile dysfunction in men.